US Patent Issued to Regeneron Pharmaceuticals on Aug. 5 for "Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire" (New York Inventors)

ALEXANDRIA, Va., Aug. 6 -- United States Patent no. 12,376,573, issued on Aug. 5, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire" was invented by Chunguang Guo (Briarcliff Manor, N.Y.), Naxin Tu (Pleasantville, N.Y.) and Andrew J. Murphy (Croton-on-Hudson, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are non-human animals (e.g., rodents, e.g., mice or rats) genetically engineered to express a human or humanized T cell receptor (TCR) from a human or humanized TCR locus comprising a non-human TCR non-coding sequence, and optionally a humanized T...